Tregs undergo specific priming in the presence of liver tumor, and enhanced Tregs can modify tumor-antigen specific MDSCs that migrate to distant sites, ultimately suppressing antigen-specific CD8+ T cell activation via clonal anergy. The gene discussed is CD8A; the disease is neoplasm.